Q-State Biosciences Announces Additions and Appointments to its Board of Directors
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Q-State Biosciences (“Q-State”), a precision therapeutics company developing treatments for diseases associated with electrically excitable cells, announced today multiple additions and appointments to its board of directors supporting the company’s strategic advancement. Steven Hyman, MD, and Matthew Might, PhD, join the Q-State board as independent directors, and current board member Mark Evenstad is appointed Chair following the retirement from the board of outgoing Chair, David Margulies, MD.
“I would like to extend my thanks to David Margulies for his leadership and many contributions to Q-State,” said Mark Evenstad. “His efforts have been invaluable in helping the company progress from an early concept to a rapidly advancing, technology-driven enterprise developing novel therapeutics for serious disorders. We are also delighted to welcome Steve Hyman and Matt Might as new directors. Steve and Matt each bring deep scientific, development and organizational expertise to the Q-State board, and they will be significant assets in supporting the company’s continued momentum at this important time in its evolution.”
Mr. Evenstad brings to the role of Chair a wealth of experience as a senior executive and entrepreneur in the healthcare industry. He is Founder and Chairman of MOBE, Pairnomix, Plymouth Guarantee, ACOVA and Applied Insights. Prior to holding these positions, Mr. Evenstad served as Chief Executive Officer and Vice Chairman of Upsher-Smith Laboratories.
Dr. Hyman currently serves as Director of the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard and is the Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology. Previously, Dr. Hyman held positions of Provost and Chief Academic Officer of Harvard University, and Director of the National Institute of Mental Health (NIMH). He serves in multiple capacities on commercial and not-for-profit boards including Janssen Pharmaceuticals, F-Prime Capital and the Charles A. Dana Foundation.
Dr. Might is Director of the Hugh Kaul Precision Medicine Institute and Professor of both Internal Medicine and Computer Science at the University of Alabama at Birmingham. Formerly, Dr. Might served as a member of the White House’s Precision Medicine Initiative and was an Associate Professor in the School of Computing at the University of Utah. He is co-founder and Chief Scientific Officer of NGLY1.org.
Q-State Biosciences is a precision medicine company based in Cambridge, MA, that pioneers transformative treatments for diseases of electrically excitable cells. Q-State combines human cellular models, unique measurement tools and deep analytics into a proprietary platform that enables the discovery of new genetically targeted medicines. For more information, please visit www.qstatebio.com.